Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senate Generic Rx Bill Too “One-Sided” For House, GSK Assures Investors

Executive Summary

Any Waxman/Hatch Act reform legislation that emerges from the House would be more balanced than the bill currently moving through the Senate, GlaxoSmithKline Chief Operating Officer Robert Ingram maintained during a July 24 conference call
Advertisement

Related Content

GSK Supports Waxman/Hatch Trade: Drop Bolar, Remove 30-Month Stays
Senate Generic Rx Bill Would Allow Challenges To “Orange Book” Listings
Senate Generic Rx Bill Would Allow Challenges To “Orange Book” Listings
White House Medicare Rx Plans Include $77 Bil. Medicaid Expansion
Advertisement
UsernamePublicRestriction

Register

PS040241

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel